Novartis (SWX:NOVN) Gains A New Pluvicto Growth Case As Valuation Stays In Focus

Novartis (SWX:NOVN) is back in focus after the US Food and Drug Administration approved an expanded use of Pluvicto in combination with androgen receptor pathway inhibitors for PSMA-positive metastatic hormone-sensitive prostate cancer.

See our latest analysis for Novartis.

Novartis shares have been firming over 2026, with a 16.68% year to date share price return and a 38.50% total shareholder return over one year, as investors weigh the expanded Pluvicto approval alongside recent earnings, guidance and impairment charges.

If this kind of healthcare catalyst has your attention, it could be worth scanning other treatment focused opportunities through the 128 healthcare AI stocks.

The recent surge in Novartis reflects both enthusiasm for Pluvicto’s broader label and a reassessment of earnings, guidance and impairments. How much of that move looks grounded in fundamentals once you compare it with today’s valuation?

Most Popular Narrative: 0.4% Overvalued

The most followed valuation narrative puts Novartis fair value at CHF126.14, which sits almost level with the last close at CHF126.60. That tight gap makes the underlying growth story worth a closer look.

Novartis' robust pipeline and rapid regulatory progress in advanced therapies (including biologics, gene, and cell therapies) positions the company to benefit from emerging healthcare technologies, potentially accelerating future earnings and margin growth as new high-value products launch.

Operational efficiency gains from portfolio streamlining and productivity improvements are driving core margin expansion and higher free cash flow, which can be reinvested in R&D and shareholder returns, supporting long-term earnings and net margin growth.

Read the complete narrative.

Curious what kind of earnings profile and revenue trajectory need to line up to justify that near match between price and fair value? The narrative leans heavily on margin expansion, cash generation and a future earnings multiple that looks very different from today. The detailed forecast spells out exactly how those moving parts are expected to interact.

Result: Fair Value of CHF126.14 (ABOUT RIGHT)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors still need to watch for patent expiries on key drugs and any setback in late stage trials, as these could quickly challenge the current Novartis narrative.

Find out about the key risks to this Novartis narrative.

Another View: Novartis Through The SWS DCF Lens

The first narrative framed Novartis as roughly fairly priced around CHF126 based on analyst targets. Our DCF model points in a very different direction. On that method, the stock price of CHF126.60 sits around 60.6% below an estimated future cash flow value of CHF321.59, which flags a wide gap for you to interrogate.

That sort of difference between P/E based fair value and a cash flow model often comes down to how confident you are in long term earnings and margins, especially in a sector where patent cycles and pricing policy matter. The key question is which set of assumptions you find more realistic for Novartis, and why.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Novartis for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 257 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mixed signals around Novartis, it helps to move quickly, review the data in full, and weigh both sides of the story for yourself with the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Novartis?

If Novartis has sharpened your focus, do not stop here. Broadening your watchlist with other clear opportunities can be the difference between reacting and staying ahead.

• Spot potential value candidates before the crowd by scanning the 257 high quality undervalued stocks.
• Strengthen your focus on balance sheet quality with the solid balance sheet and fundamentals stocks screener (416 results).
• Target resilience over headline excitement by reviewing the 304 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com